Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy

Abstract

Cognitive development at school age ranged between normal and mildly delayed in our long-term survivors with classic infantile Pompe disease treated with ERT. The oldest was 12 years. We found that cognition is easily underestimated in children younger than 5 years with poor motor functioning.